1. Scrip
  2. >>Business
  3. >>Strategy

Keytruda Rules The Roost, But Merck & Co. Highlights Progress In Other Areas

 
• By Jessica Merrill

Merck & Co. outlined its near-term growth drivers during an investor day, including Keytruda in breast and prostate cancer, as well as vaccines for RSV and CMV, a drug for chronic cough and a long-acting HIV medicine.

Business success growing growth increase up concept. Wooded cube block on white background with word GROWTH and copy space for your text - Image

Merck & Co. Inc. is poised for strong growth through 2023 and beyond, the company said during an investor day in New York on 20 June, where management outlined the strategy for driving growth through 2023 in the company's first investor day in five years.

The growth plan is based largely on expanding the indications for immuno-oncology blockbuster Keytruda (pembrolizumab) and other backbone brands like Gardasil (human papilloma virus 9-valent vaccine) and Lynparza (olaparib), and eventually new launches

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.